[Action of raubasine (new formulation) in arterial occlusive diseases (author's transl)].
A double blind cross-over study under acute experimental conditions was carried out in 26 patients with angiographically confirmed occlusion in one or two limbs in order to see whether a change in the formulation of raubasine preparations improves the circulation in diseased limbs. Either 100mg raubasine or placebo tablets were administered in a randomized order. Blood flow at rest and "peak-flow" after total arterial occlusion for 3 min showed a significant improvement under raubasine compared with the pre-occlusion period whilst these parameters were not affected by placebo. Systolic blood pressure and heart rate remained almost constant under raubasine whilst they were reduced under placebo. A similar response was seen in a subgroup of 19 patients with occlusion of the femoral artery. It can thus be said that in the present investigation the new formulation of raubasine preparation (MF 706d) has been shown in a double blind study to improve both the blood flow at rest and the "peak-flow" to a significant degree in patients with arterial occlusions.
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005263:Femoral Artery; D006801:Humans; D007866:Leg / Q000098:blood supply; D010919:Placebos; D010991:Plethysmography; D012039:Regional Blood Flow / Q000187:drug effects; D046948:Secologanin Tryptamine Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*
D010919:Placebos; D046948:Secologanin Tryptamine Alkaloids
Wirkung von Raubasin (neue Rezeptur) bei arterieller Verschlusskrankheit